Your browser doesn't support javascript.
loading
Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma.
Li, Binkui; Qiu, Jiliang; Zheng, Yun; Shi, Yunxing; Zou, Ruhai; He, Wei; Yuan, Yichuang; Zhang, Yuanping; Wang, Chenwei; Qiu, Zhiyu; Li, Kai; Zhong, Chengrui; Yuan, Yunfei.
Affiliation
  • Li B; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Qiu J; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Zheng Y; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Shi Y; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Zou R; Department of Ultrasound, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • He W; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Yuan Y; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Zhang Y; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Wang C; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Qiu Z; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Li K; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Zhong C; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Yuan Y; From the State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Ann Surg Open ; 2(2): e057, 2021 Jun.
Article in En | MEDLINE | ID: mdl-37636551
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Ann Surg Open Year: 2021 Document type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Ann Surg Open Year: 2021 Document type: Article Affiliation country: China